Yahoo Canada Web Search

Sign In

Search results

  1. finance.yahoo.com › news › biogen-completes-1-15bnBiogen completes $1.15bn HI-Bio acquisition to expand ...

    6 days ago · Biogen is known for its neuroscience focus, having co-developed the next-generation Alzheimer’s treatment Leqembi (lecanemab-irmb) with Eisai. The drug is predicted to see US sales of $4.6bn by ...

  2. www.reuters.com › business › healthcareLilly follows Biogen-Eisai in securing US FDA approval for ...

    5 days ago · Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.

  3. BIIB - Biogen Inc.

    Yahoo Finance

    228.07+2.42 (+1.07%)

    at Mon, Jul 8, 2024, 4:00PM EDT - U.S. markets closed

    After Hours 229.00 +0.93 (+0.41%)

    Nasdaq Real Time Price

    • Open 226.47
    • High 229.41
    • Low 225.80
    • Prev. Close 225.65
    • 52 Wk. High 281.68
    • 52 Wk. Low 189.44
    • P/E 28.47
    • Mkt. Cap 33.21B
    • NasdaqGS
    • •Price in USD

  4. www.nature.com › articles › d41573/024/00116-1FDA approves third anti-amyloid antibody for Alzheimer disease

    4 days ago · Biogen’s sales of aducanumab were meager, and the company pulled the antibody from the market earlier this year. Lecanemab secured accelerated approval in January 2023, following in the amyloid ...

  5. www.yahoo.com › news › factbox-lilly-follows-biogenFactbox-Lilly follows Biogen-Eisai in securing US FDA ... - Yahoo

    5 days ago · Biogen BIIB080 An antisense. Mid-stage trial oligonucleotide. for early-stage therapy. Alzheimer’s directed. against "tau" proteins. Longeveron lomecel-B A cell therapy. Mid-stage trial designed to.

  6. www.bloomberg.com › news › articlesEli Lilly (LLY) Alzheimer’s Disease Drug Wins FDA Approval ...

    6 days ago · July 2, 2024 at 1:08 PM PDT. Eli Lilly & Co. ’s Alzheimer’s treatment was cleared in the US as the second drug to slow progression of the mind-robbing disease that afflicts 6 million Americans ...

  7. www.cbc.ca › news › healthFDA approves new Alzheimer's drug, offering hope for slower ...

    6 days ago · The U.S. Food and Drug Administration gave a green light to Eli Lilly's donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain ...

  8. investors.biogen.com › news-releases › news-releaseBiogen Completes Acquisition of Human Immunology Biosciences

    Jul 2, 2024 · CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).

  9. People also ask

  1. Related searches

    biogen canada
    biogen stock
    biogen alzheimer's drug phase 3
    biogen pharmaceuticals
    biogen inc
    biogen careers
  2. People also search for